Victoria Socha

DocwireNews

The prospective, multicenter study, PAZOREAL,  is designed to examine the effectiveness, defined as primary time on drug (TD), safety, and quality of life in patients with mRCC treated with first-line pazopanib followed by second-line nivolumab or everolimus.
Following randomized clinical trials for new therapies, implementation of the therapies includes only a selection of patients treated with the options. Real-world evidence is the needed to monitor the translation of study findings into routine practice, potentially leading to improvements in cancer treatment and survival on a broader scale, according to Martin Boegemann, MD<a href="https://www.uni-muenster.de/en/">, </a>and colleagues.
Dr. Boegemann presented results of the PAZOREAL study during a poster session at the ASCO 2019 Annual Meeting. The poster was titled Sequential Treatment with Pazopanib (PAZO) Followed by Nivolumab (NIVO) in Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC): Third Interim Results of the Non-interventional Study PAZOREAL.
A total of 421 patients were enrolled between December 2015 and September 2017. Of those, 402 started first-line treatment with pazopanib; 127 received nivolumab as second-line treatment and five received everolimus as second-line treatment. A total of 56 patients entered follow-up. As of the time of data-cut (November 8, 2018), median TD was 6.6 months (95% confidence interval [CI], 6.0-7.9) for first-line pazopanib and 4.1 months (95% CI, 3.205.8) for second-line nivolumab (all patients); median TD for trial eligible patients was 8.1 months (95% CI, 6.6-9.5) for pazopanib and 3.2 months (95% CI, 2.706.5) for nivolumab. Median TD for patients with or without prior nephrectomy was 7.6 months versus 4.5 months, respectively.
Based on investigator assessment, the clinical benefit of <a href="https://www.docwirenews.com/latest-nephrology-news/active-surveillance-vs-immediate-treatment-in-mrcc/">first-line treatment</a> with pazopanib was 58.2% (95% CI, 53.3-62.9). Median overall survival on pazopanib was 29.5 months (95% CI, 23.6-NA) for all patients; median overall survival receiving nivolumab as second-line treatment was 28.2 months (95% CI, 22.2-NA).
The most commonly reported adverse events for pazopanib were diarrhea (35%), nausea (20.3%), hypertensive crisis (2.3%), and increase in gamma-glutamyltransferase level (1.8%).
Quality of life, as evaluated by the EQ-5D-5L scale, remained stable over different treatment lines.
“The interim results of the PAZOREAL study confirm a favorable overall survival in patients with mRCC treated with first-line pazopanib in a real-world setting, good benefit-risk profile of pazopanib, and sustained quality of life, monitored over several treatment lines. In Germany, nivolumab as second line treatment is commonly applied after first-line treatment with pazopanib,” the researchers said.
Source: Boegemann M, Bedke J, Schostak M, et al. Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL. Abstract of a poster presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 3, 2019, Chicago, Illinois.
&nbsp;
&nbsp;
&nbsp;

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Pazopanib plus Nivolumab: PAZOREAL Results

ASCO 2019

The prospective, multicenter study, PAZOREAL,  is designed to examine the effectiveness, defined as primary time on drug (TD), safety, and quality of life in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe